DEXCOM-HD: Dexcom G6 Continuous Glucose Monitoring in Hemodialysis
Study Details
Study Description
Brief Summary
This is a pilot study enrolling adult hemodialysis patients with diabetes recruited from the University of California Irvine Medical Center (UCIMC) who will undergo simultaneous measurement of glucose levels using 1) continuous glucose monitor (CGM) measured by a Dexcom G6 device vs. 2) "gold-standard" blood glucose levels using capillary fingerstick or venous blood glucose measurements obtained on a point of care (POC) blood glucose meter. The study will assess Dexcom G6 accuracy by comparing glucose levels on the CGM device vs. blood glucose measurements in the study population.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Dexcom G6 Continuous Glucose Monitor
|
Device: Dexcom G6 Continuous Glucose Monitor
Eligible patients will undergo DDexcom G6 Continuous Glucose Monitor device placement
|
Outcome Measures
Primary Outcome Measures
- Blood glucose measurement [3 to 5 days]
Proportion of CGM values within 20% of blood glucose levels >100 mg/dl or within 20 mg/dl of blood glucose level for levels <=100 mg/dl. (Will examine different thresholds of CGM values within a certain range of blood glucose levels, i.e., 10%, 15%, 25%.)
Secondary Outcome Measures
- Hypoglycemia events [3 to 5 days]
Comparison in number of hypoglycemia events (glucose <70 mg/dl) determined by CGM or by blood glucose measurements
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult hemodialysis patients age 18 years or older
-
Have a comorbidity of diabetes
-
Receipt of care from the inpatient University of California Irvine Medical Center nephrology consult service
-
Expected hospital stay ≥48 hours
-
Have the ability to directly provide informed consent for participation in the study
Exclusion Criteria:
-
Critically-ill patients receiving care in the intensive care unit (ICU) or cardiac care unit (CCU)
-
Moribund patients expected to die within 48 hours
-
Presence of any condition deemed by PI's judgment that would seriously limit life expectancy (i.e., poor survival)
-
Pregnant
-
Unwilling or unable to provide informed consent
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of California Irvine | Orange | California | United States | 92868 |
Sponsors and Collaborators
- University of California, Irvine
- DexCom, Inc.
Investigators
- Principal Investigator: Connie Rhee, MD, MSc, Faculty
Study Documents (Full-Text)
None provided.More Information
Publications
- Rhee CM, Kovesdy CP, Ravel VA, Streja E, Brunelli SM, Soohoo M, Sumida K, Molnar MZ, Brent GA, Nguyen DV, Kalantar-Zadeh K. Association of Glycemic Status During Progression of Chronic Kidney Disease With Early Dialysis Mortality in Patients With Diabetes. Diabetes Care. 2017 Aug;40(8):1050-1057. doi: 10.2337/dc17-0110. Epub 2017 Jun 7.
- Rhee CM, Kovesdy CP, Ravel VA, Streja E, Sim JJ, You AS, Gatwood J, Amin AN, Molnar MZ, Nguyen DV, Kalantar-Zadeh K. Glycemic Status and Mortality in Chronic Kidney Disease According to Transition Versus Nontransition to Dialysis. J Ren Nutr. 2019 Mar;29(2):82-90. doi: 10.1053/j.jrn.2018.07.003. Epub 2018 Nov 15.
- Rhee CM, Kovesdy CP, You AS, Sim JJ, Soohoo M, Streja E, Molnar MZ, Amin AN, Abbott K, Nguyen DV, Kalantar-Zadeh K. Hypoglycemia-Related Hospitalizations and Mortality Among Patients With Diabetes Transitioning to Dialysis. Am J Kidney Dis. 2018 Nov;72(5):701-710. doi: 10.1053/j.ajkd.2018.04.022. Epub 2018 Jul 20.
- Rhee CM, Leung AM, Kovesdy CP, Lynch KE, Brent GA, Kalantar-Zadeh K. Updates on the management of diabetes in dialysis patients. Semin Dial. 2014 Mar;27(2):135-45. doi: 10.1111/sdi.12198. Review.
- HS# 2019-5585